• UGI USER
  • May 09, 2024
  • 3 Likes
  • 0 Comments

ASTRAZENECA HALTS COVID-19 VACCINE GLOBALLY DUE TO RARE SIDE-EFFECTS

Why in the news?

AstraZeneca, known for its COVID-19 vaccine Covishield, withdraws globally due to rare side-effects and surplus availability of updated vaccines.

source:reuters

Key Points:AstraZeneca Withdraws COVID-19 Vaccine:

  • AstraZeneca, in collaboration with Oxford University, has commenced the global withdrawal of its COVID-19 vaccine.
  • Marketed as ‘Covishield’ in India through a partnership with the Serum Institute of India, the vaccine is being recalled due to reported rare side-effects such as blood clotting and decreased platelet counts.
What is Covishield ?

●    Covishield is the AstraZeneca COVID-19 vaccine produced in India.

●    Manufactured by Serum Institute of India (SII) in Pune.

●    The Indian government cautioned its use for individuals with thrombocytopenia.

●    Administered in India since January 16, 2021.

●    Thromboembolic events reported at 0.61 cases per million doses.

●    Covishield has a positive benefit-risk profile, per the Union Health Ministry.

●    European countries temporarily halted AstraZeneca vaccine use in March 2021 due to blood clotting concerns.

●    WHO noted cases of Thrombosis with Thrombocytopenia Syndrome (TTS) post-Covishield vaccination.

●    WHO stated the risk of TTS with Covershield is very low based on available data.

AssociatedArticle:https://universalinstitutions.com/sc-petition-requests-expert-panel-to-probe-covishield-vaccines-safety/